Improved Anti-Treg Vaccination Targeting Foxp3 Efficiently Decreases Regulatory T Cells in Mice

Journal of Immunotherapy

Volumn 39, Issue 7, 2016, Pages 269-275

  Mousavi Niri, Neda ^a   Memarnejadian, Arash ^b   Pilehvar Soltanahmadi, Younes ^a   Agha Sadeghi, Mohammadreza ^b   Mahdavi, Mehdi ^b   Kheshtchin, Nasim ^c   Arab, Samaneh ^d   Namdar, Afshin ^e   Jadidi, Farhad ^d   Zarghami, Nosratollah ^a   Hajati, Jamshid ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

FOXP3; fragment c(IgG); T regulatory; vaccination

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; CANCER VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; NEOPLASM; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELLS, CULTURED; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOGLOBULIN FC FRAGMENTS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; NEOPLASMS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, DNA;

EID: 84978100766     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000133     Document Type: Article

References (35)

1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
2. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
3. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
4. Gray CP, Arosio P, Hersey P. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin Cancer Res. 2003;9:2551-2559.
5. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
6. Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 2005;65: 2457-2464.
7. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-2761.
8. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998;95: 10067-10071.
9. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100: 4712-4717.
10. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.
11. Espenschied J, Lamont J, Longmate J, et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol. 2003;170:3401-3407.
12. Attia P, Maker AV, Haworth LR, et al. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005;28:582-592.
13. Powell DJ Jr., Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179:4919-4928.
14. Curtin JF, Candolfi M, Fakhouri TM, et al. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One. 2008;3:e1983.
15. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood. 2008;112: 610-618.
16. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+ 2H4+ suppressor-inducer T-cells. Cancer Res. 1988;48:1671-1675.
17. Shibutani S, Inoue F, Aramaki O, et al. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation. 2005;79:904-913.
18. Kawai M, Kitade H, Mathieu C, et al. Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo. Transplantation. 2005;79:1073-1077.
19. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
21. Khattri R, Cox T, Yasayko SA, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003;4:337-342.
22. Mousavi Niri N, Memarnejadian A, Hadjati J, et al. Construction and production of Foxp3-Fc(IgG) DNA vaccine/fusion protein. Avicenna J Med Biotechnol. 2016;8:57-64.
23. Niri NM, Hadjati J, Sadat M, et al. Inducing humoral immune responses against regulatory T cells by Foxp3-Fc(IgG) fusion protein. Monoclon Antib Immunodiagn Immunother. 2015;34:381-385.
24. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41-101.
25. Matsushita N, Pilon-Thomas SA, Martin LM, et al. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods. 2008;333: 167-179.
26. Ruter J, Barnett BG, Kryczek I, et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci. 2009;14:1761-1770.
27. Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res. 2010;70:7788-7799.
28. Nair S, Boczkowski D, Fassnacht M, et al. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007;67:371-380.
29. You Z, Huang X, Hester J, et al. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 2001;61:3704-3711.
30. Flanagan ML, Arias RS, Hu P, et al. Soluble Fc fusion proteins for biomedical research. Methods Mol Biol. 2007;378:33-52.
31. Guyre PM, Graziano RF, Goldstein J, et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother. 1997;45:146-148.
32. Zizzari IG, Veglia F, Taurino F, et al. HER2-based recombinant immunogen to target DCs through FcgammaRs for cancer immunotherapy. J Mol Med. 2011;89:1231-1240.
33. Dorgham K, Abadie V, Iga M, et al. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine. 2008;26:3252-3260.
34. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868-876.
35. Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012;4:1015-1028.